文献速递类风湿关节炎

沙利鲁单抗与JAK抑制剂在晚发型和年轻型类风湿关节炎中的比较效果与安全性

Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

这项多中心真实世界队列研究比较了沙利鲁单抗(SAR)与JAK抑制剂(JAKi)在晚发型RA(LORA)和年轻型RA(YORA)成人患者中的效果与安全性。12个月随访显示,两种治疗均促进甲氨蝶呤(MTX)和糖皮质激素(GC)逐渐减量,SAR与更高的MTX停药频率相关,而GC停药和CDAI改善在两种治疗间大致相似。

要点

  • SAR与JAKi均支持在常规实践中逐步减停伴随的MTX和GC。
  • SAR较JAKi与更高的MTX停药频率相关,且不损失疾病控制。
  • GC停药和CDAI改善在SAR与JAKi间及LORA/YORA分层中大致相似。

核心结论

  • 在常规临床实践中,SAR和JAKi均支持伴随治疗的降阶梯。
  • SAR可能允许更早停用MTX而不损失疾病控制,且GC减量和疾病活动度改善在LORA和YORA中相当。

研究设计与样本

  • 多中心真实世界队列研究,纳入开始SAR或JAKi治疗的成人RA患者。
  • 在LORA和YORA分层内分析,并分别进行倾向评分匹配(PSM)以平衡基线特征。

主要发现

  • SAR和JAKi均与随访期间伴随MTX和GC的逐渐减量相关。
  • SAR与JAKi相比,MTX停药频率更高。
  • GC停药和CDAI改善在不同年龄分层和MTX亚组中两种治疗间大致相似。
  • PSM后及LORA和YORA内的敏感性分析结果一致。

关键数值与推荐

  • 12个月结局包括MTX剂量变化(ΔMTX,mg/周)和GC剂量变化(ΔGC,mg/天)、累积治疗停药和CDAI变化。

临床怎么用

  • 在LORA和YORA中,SAR和JAKi均可用于支持伴随MTX和GC的减量。
  • 若考虑更早停用MTX,SAR可能是一个选择,且不损失疾病控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Glucocorticoid (GC)- and MTX-sparing strategies are clinically important in RA, yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset-late-onset RA (LORA) vs young-onset RA (YORA)-also remains unclear. This study aimed to compare the effectiveness and safety of SAR and JAKi in patients with LORA and YORA. METHODS: We conducted a multicentre real-world cohort study of adults with RA initiating SAR or a JAKi. Outcomes over 12 months included change from baseline in MTX dose (ΔMTX, mg/week) and GC dose (ΔGC, mg/day), cumulative treatment discontinuation and change in Clinical Disease Activity Index (CDAI). Analyses were performed within LORA and YORA strata, and propensity score matching (PSM) was applied separately in each stratum to balance baseline characteristics. Sensitivity analyses were conducted in the matched cohorts. RESULTS: Both SAR and JAKi were associated with progressive tapering of concomitant MTX and GC during follow-up. SAR was associated with a higher frequency of MTX discontinuation compared with JAKi. In contrast, GC discontinuation and CDAI improvement were broadly similar between treatments across age strata and MTX subgroups. Findings were consistent after PSM and in sensitivity analyses within both LORA and YORA. CONCLUSION: In routine clinical practice, SAR and JAKi support de-escalation of concomitant therapy. SAR may permit earlier MTX withdrawal without loss of disease control, with comparable GC tapering and disease activity improvement in both LORA and YORA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Nozaki Y, Kishimoto K, Itami T, et al. Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis. Rheumatology (Oxford). 2026. PMID: 42261260. doi:10.1093/rheumatology/keag289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。